Sure. Thank you very much. I have two questions. And the first is on the KEYTRUDA plus Lynparza trials and non-small cell lung cancer. And I'm just wondering what the expectation is in terms of expanding patient population based on that clinical trial. And then the second question is one around regulatory strategy in Europe, just understanding that yesterday or the day before heard that the CHMP had removed accelerated status for Novartis' [Indecipherable]. But we've also seen this is not an isolated incident with other drugs and in particular oncology drugs being taken off that accelerated track. And I'm wondering if the Company can share any thoughts around this dynamic and any potential impact on your own regulatory plans in Europe?